Anti-GD2 Immunocytokine, IgG (ch14.18)-IL2 (ACFP-SH019)
This antibody-cytokine fusion protein was achieved by conjugating/fusing the Anti-GD2 IgG to IL2. It was expressed in CHO and purified with affinity chromatography. The immunocytokine retains the ability to bind the GD2 as well as the biological activity of IL2. ch14.18-IL2 fusion protein bound specifically to GD2-positive melanoma and neuroblastoma tumor cell lines, and its IL2 component stimulated in vitro proliferation of an IL2-dependent cell line, as well as peripheral blood mononuclear cells, in healthy control individuals and in cancer patients receiving continuous infusion of IL2. The ch14.18-IL2 fusion protein also mediated antibody-dependent cellular cytotoxicity with Fc receptor-positive effector cells to an extent similar to ch14.18. This immunocytokine was designed for treating GD2-positive tumors.
Specifications
- Target
- GD2
- Molecule Class
- L Kappa; IgG1-IL2
- Species Reactivity
- Human
- Host
- Chimeric (Human-Mouse)
- Expression Host
- CHO
- Clone
- ch14.18
- Related Disease
- GD2-positive tumors
- Cytokines 1
- IL2
- Cytokines 1 Description
- Interleukin-2 (IL-2) is an interleukin, a type of cytokine signaling molecule in the immune system. It is a protein that regulates the activities of white blood cells (leukocytes, often lymphocytes) that are responsible for immunity. IL-2 is part of the body's natural response to microbial infection, and in discriminating between foreign ("non-self") and "self". IL-2 mediates its effects by binding to IL-2 receptors, which are expressed by lymphocytes.
- Cytokine 1 Species
- Human
- Applications
- This product can be used therapeutically to deliver biologically active ligands to a desired tissue.
Target
- Alternative Names
- Disialoganglioside GD2; Ganglioside G2; GD2
For lab research use only, not for diagnostic, therapeutic or any in vivo human use.
Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us
Tel: 1-631-381-2994
Fax: 1-631-207-8356
Email: